Mjaess G, Karam A, Aoun F, Albisinni S, Roumeguère T
Urology Department, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium; Hotel-Dieu de France, University of Saint-Joseph, Beirut, Lebanon.
Hotel-Dieu de France, University of Saint-Joseph, Beirut, Lebanon.
Prog Urol. 2020 Sep;30(10):484-487. doi: 10.1016/j.purol.2020.05.007. Epub 2020 May 22.
COVID-19 is the pandemic that hit the world starting December 2019. Recent studies and international statistics have shown an increased prevalence, morbidity as well as mortality of this disease in male patients compared to female patients. The aim of this brief communication is to describe the pathophysiology of this sex-discrepancy, based on the infectivity mechanism of the coronavirus including the Angiotensin-Converting Enzyme 2 (ACE2), the Type II transmembrane Serine Protease (TMPRSS2), and the androgen receptor. This could help understand the susceptibility of urological patients, especially those receiving androgen deprivation therapy for prostate cancer, and testosterone replacement therapy.
2019冠状病毒病是自2019年12月起席卷全球的大流行病。最近的研究和国际统计数据表明,与女性患者相比,男性患者中该疾病的患病率、发病率和死亡率均有所上升。本简短交流的目的是基于冠状病毒的感染机制,包括血管紧张素转换酶2(ACE2)、II型跨膜丝氨酸蛋白酶(TMPRSS2)和雄激素受体,描述这种性别差异的病理生理学。这有助于了解泌尿外科患者的易感性,尤其是那些因前列腺癌接受雄激素剥夺治疗和睾酮替代治疗的患者。